Celgene's roving band of dealmakers has selected San Diego-based Abide Therapeutics for its latest option package, taking an equity stake in the biotech as it settles into a front row seat on its progress regarding a broad R&D front and gaining first dibs on Abide's lead program.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
New Jersey-based Celgene in 2011 tucked a notice into a financial report that a U.S. Attorney in California was investigating its marketing of its cancer meds Revlimid and Thalomid. Nothing more was said until Thursday when the company divulged that the probe was tied to lawsuits filed against it by whistleblowers.
Biopharma's long-heralded return to R&D ROI may come up short this year, according to EvaluatePharma, and the next class of approved drugs features fewer blockbusters in waiting than in any of the previous four years.
When new drugs roll out, they meet the general population for the first time. Patients are no longer hand-picked as they are in clinical trials. And that often translates into a flurry of side-effect reports to the FDA. Last year's crop of new drugs is no exception.
Biotech billionaire Patrick Soon-Shiong is back to doing cancer drug deals. And he's working with some very familiar partners at Celgene to build up a new platform for nanoparticle albumin-bound drugs--building on the same tumor-targeting tech used for Abraxane.
Celgene figures it will end 2014 with $7.4 billion in net sales, adding about $1 billion to its $6.4 billion total for 2013. But by 2017, the company figures it will be reporting net sales of $13 billion to $14 billion--more than twice its 2013 total.
Pharma-academic partnerships have their pitfalls--and how to share the cash is one of the biggest. Case in point: Boston Children's Hospital's lawsuit against Celgene ($CELG), which makes several lucrative cancer treatments.
Agios is banking a $20 million payment from Celgene for a deal to extend their collaboration on cancer metabolism--originally struck in 2010--by another year.
Alliqua Biomedical is a relatively small maker of hydrogel wound care and drug delivery systems looking to delve into the hot regenerative medicine space, and a recent investment from Celgene has given the company a chance at a higher profile in the arena.